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Abstract
Introduction: Ligand-bound and phosphorylated ErbB/HER heterodimers are potent signaling forms of this
receptor family, and quantitative measurements of these active receptors may be predictive of patient response to
targeted therapies. Using VeraTag™ technology, we developed and characterized quantitative assays measuring
epidermal growth factor (EGF)-dependent increases in activated HER receptors in tumor cell line lysates and
formalin-fixed, paraffin-embedded (FFPE) tumor sections. We demonstrated the ability of the assays to
quantitatively measure changes in activated HER1 and HER2 receptor levels in cell lines following treatment with
2C4, erlotinib, and lapatinib. We utilized these assays to determine the prevalence and distribution of activated
HER1, HER2, and HER1-HER2 heterodimers in 43 HER2-positive breast tumors.
Methods: Assays for activated HER1 and HER2 receptors in FFPE and cell lysate formats were developed using
VeraTag™ technology, which requires the proximity of an antibody pair for light-dependent release of a
fluorescently labeled tag, followed by capillary electrophoresis-based quantitation.
Results: Ligand-dependent and independent HER1-HER2 heterodimer levels measured by lysate and FFPE
VeraTag™ assays trended with HER1 and HER2 expression levels in tumor cell lines, which was confirmed by co-
immunoprecipitation. The formation of EGF-dependent HER1-HER2 heterodimers were inhibited by the HER2-
targeted monoclonal antibody 2C4 and stabilized by the HER1 tyrosine kinase inhibitor (TKI) erlotinib. EGF-
dependent HER1 and HER2 phosphorylation was inhibited by lapatinib and erlotinib. Further, we observed that
dominant receptor signaling patterns may switch between HER1-HER1 and HER1-HER2, depending on drug
mechanism of action and relative levels of HER receptors. In FFPE breast tumors that expressed both HER1 and
HER2, HER1-HER2 heterodimers were detected in 25 to 50% of tumors, depending on detection method. The levels
of activated phospho-HER1-HER2 heterodimers correlated with HER1 or HER2 levels in an analysis of 43 HER2-
positive breast tumors.
Conclusions: VeraTag™ lysate assays can be used as a tool for understanding the mechanism of action of
targeted HER-family inhibitors in the preclinical setting, while VeraTag™ FFPE assays of activated HER receptors
combined with total HER2 measurements (HERmark
®) in tumor samples may provide a more accurate prediction
of clinical response to both HER1 and HER2 targeted therapies.
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Both the epidermal growth factor receptor (EGFR/
H E R 1 )a n dH E R 2a r em e m b e r so ft h eE r b Bf a m i l yo f
the type I receptor tyrosine kinases, which also includes
HER3 and HER4. These homologous receptors are com-
prised of an extracellular binding domain (ECD), a
transmembrane domain, and an intracellular tyrosine
kinase (TK) domain. Binding of ligand to the ECD
induces structural reorganization allowing for functional
homo- and heterodimerization and activation of the
kinase domain [1-3]. HER1 has several ligands including
EGF, transforming growth factor a, amphiregulin, beta-
cellulin, epiregulin and heparin binding-EGF [4-7]. A
HER2 ligand has not been identified, but overexpressed
HER2 is constitutively active [8]. In cells expressing
both HER1 and HER2, binding of ligand to HER1 can
induce HER1-HER1 homodimerization and HER1-HER2
heterodimerization. These active dimers transmit
through signaling pathways including Ras/Raf/MEK/ERK
and PI3K/Akt, which are important for tumor growth
and metastasis [9]. Recent studies have shown that
HER1-HER1 homodimers and HER1-HER2 heterodi-
mers also exist in inactive, non-ligand bound conforma-
tions which may structurally rearrange upon ligand
binding to form actively signaling complexes [10-14].
HER2 overexpression has been observed in several
cancer types [15]. From 15 to 30% of human breast
tumors display HER2 gene amplification or protein
overexpression, which is prognostic for poor outcome
and predictive of a response to trastuzumab [16,17].
HER1 overexpression has also been observed in colorec-
tal, gastric, breast, ovarian, non-small cell lung, and
head and neck carcinomas as well as glioblastoma [15]
and has been shown to contribute to cellular transfor-
mation and proliferation [18,19]. Potential cooperativity
of HER1 and HER2 in mouse mammary tumorigenesis
has been reported [20,21]. Furthermore, human breast
and ovarian tumors that overexpress both HER1 and
HER2 may have a less favorable outcome [22,23].
Finally, a retrospective immunohistochemical analysis of
807 FFPE breast tumor samples showed that patients
whose tumors expressed phosphorylated HER2 or co-
expressed HER1 and HER2 had the shortest survival
[24]. These studies support a potential role for HER1
signaling in breast cancer.
Several drugs that target HER1 and HER2 receptors
have been utilized in both preclinical and clinical mod-
els of breast and other cancers. Treatment with the
humanized monocolonal HER2 antibody trastuzumab is
now standard of care for individuals with HER2-positive
invasive breast cancer in both the metastatic and adju-
vant settings. However, fewer than 50% of patients with
metastatic HER2-positive breast tumors show initial
benefit from trastuzumab treatment, and many of those
eventually develop resistance [25-27]. Thus, exclusive
measurement of total HER2 receptor level may not pro-
vide sufficient information for prediction of drug
response. Recent studies have indicated that stratifying
HER2 positive breast cancer patients by HER3 or p95
protein expression can result in the identification of
multiple sub-populations of patients that exhibit signifi-
cant differences in time to progression following trastu-
zumab treatment [28,29].
Preclinical studies in human breast cancer cell lines
selected for trastuzumab resistance both in vitro and in
xenograft models have demonstrated overexpression of
HER1 and its ligands [30]. Further in vitro studies have
shown that stable transfection and expression of HER1
in the background of a HER2-positive cell line induces
trastuzumab resistance [31]. HER1 up-regulation has
also been observed in estrogen-receptor positive breast
cancers that develop resistance to treatment with
tamoxifen [32,33]. In vitro selection of the human breast
cancer cell line MCF7 for tamoxifen resistance resulted
in up-regulation of HER1, and increased HER1-HER2
heterodimerization and phosphorylation [34]. Drugs that
specifically target active HER dimerization or phosphor-
ylation have been investigated both preclinically and in
clinical trials. Three such drugs are pertuzumab (huma-
nized 2C4), which inhibits HER2-containing heterodi-
mers; erlotinib, a HER1 tyrosine kinase inhibitor (TKI),
and lapatinib, a dual HER1/HER2 TKI.
Resistance to trastuzumab and the emergence of mul-
tiple new HER1 and HER2-targeted therapies support a
need for assays which directly measure not only total
amounts of HER1 and HER2 receptors, but more speci-
fically HER1 and HER2 activation. The ability to selec-
tively detect and quantify HER1 and HER2 dimerization
and phosphorylation may facilitate a better understand-
ing of drug mechanism of action. Such assays may have
the potential to predict drug response. Traditional meth-
ods to measure dimerization rely upon low throughput,
qualitative technologies such as co-immunoprecipitation
and cross-linking, which require cellular lysates, whereas
the standard tumor format used for patient testing is
FFPE tissue. Phosphorylated receptors are also measured
in lysates by co-immunoprecipitation/Western blotting,
or semi-quantitatively in FFPE sections using immuno-
histochemistry (IHC). Recently, a proximity ligation
assay (PLA) has been utilized to detect epitope-tagged
and ligand-dependent HER1 homodimers in fixed cells
overexpressing transfected HER1 [35], and native HER1-
HER2 heterodimers by fluorescent activated cell sorting
(FACS) [36]. However, there is limited characterization
of the PLA assay in FFPE tumor tissue [37]. VeraTag™
technology, which utilizes a fluorescence-based dual
antibody system, can be utilized to specifically and
quantitatively measure protein-protein interactions [38],
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HERmark
® assay, which measures total HER2 and
HER2-HER2 associations in FFPE breast tumors [39].
Here, we utilized VeraTag™ technology to develop
assays that measure HER1 and HER2 dimerization and
phosphorylation in both lysate and FFPE formats. We
demonstrated the potential utility of such assays to char-
acterize the effects of 2C4, erlotinib, and lapatinib on
HER1 and HER2 activation and determined the preva-
lence of HER1-HER2 heterodimers and activated forms
in 43 HER2-positive breast tumors. These assays have
the potential to characterize targeted drugs in pre-clini-
cal studies and identify predictive biomarkers that could
guide personalized treatment decisions.
Materials and methods
Cell line growth and EGF stimulation
Cell lines AU565, SKBR3, SKOV3, H1650, MDA-MB-
453, and MDA-MB-468 were purchased from American
Type Culture Collection (ATCC, Manassas, VA, USA)
a n dc u l t u r e di ne i t h e rM c C o y ’s 5A Modified (SKOV3
and SKBR3; Lonza, Basel, Switzerland), RPMI-1640
(AU565, H1650; Lonza), or DMEM (MDA-MB-453,
MDA-MB-468, Gibco, Carslbad, CA, USA) media, sup-
plemented with 10% heat-inactivated fetal bovine serum
(1X L-Glutamine, and 1X penicillin-streptomycin
(Gibco). EGF was purchased from Peprotech (Rocky
Hill, NJ, USA).
For EGF stimulation experiments, cells were grown in
cell line-specific media to approximately 80% conflu-
ence. Cells were washed thrice with phosphate-buffered
saline (PBS) and starved in serum-free media for 18
hours. The next morning, cells were briefly washed in
PBS and exposed to fresh serum-free media for another
25 minutes, followed by a final exposure to fresh serum-
free media containing EGF at the indicated concentra-
tion for 10 minutes at 37°C. To terminate EGF stimula-
tion, cells were placed immediately on ice and were
washed briefly two times with ice-cold PBS. Subse-
quently, the cells were processed for either lysate or
FFPE.
Transfected 293 clones
A total of 293 cells were transfected with pcDNA3.1-
Zeocin-HER1 plasmids per Fugene6 Transfection
Reagent protocol (Roche Indianapolis, IN, USA). Indivi-
dual clones were isolated and Western blot and flow
cytometry analyses were performed to confirm the pre-
sence of HER1 proteins. 293H1clone11 was further
transfected with pcDNA-Neocin containing HER2
cDNA sequence using the method described above.
293H1H2 clones 15, 16, and 19 displayed similar levels
of HER1 as 293H1c11 and different levels of HER2 by
flow cytometry.
Preparation of lysate and FFPE samples
For lysate preparation, the cells were scraped in ice cold
PBS containing phosphatase and protease inhibitors (50
mM NaF, 50 mM beta-glycerophosphate, 1 mM Na3V04,
and one protease inhibitor tablet (Roche, Indianapolis,
IN, USA) per 10 mL, and centrifuged (five minutes, 1,000
rpm, 4°C). Supernatant was decanted and the cell pellet
was lysed on ice for 30 minutes in lysis buffer (1% Triton
X-100, 50 mM Tris-HCl, pH 8.0, 150 mM NaCl) contain-
ing phosphatase and protease inhibitors. Lysates were
centrifuged (10 minutes, 10,000 rpm, 4°C) to separate
insoluble material. Total protein concentration was mea-
sured using bicinchonicic acid reagent (Pierce, Rockford,
IL, USA). Lysates were stored at -80°C.
For FFPE preparation, the cells were fixed on the tis-
sue culture plate in 10% Neutral Buffered Formalin
(Richard-Allan Scientific, Kalamazoo, MI, USA) for 30
minutes at 4°C, after which time they were scraped and
centrifuged (5 minutes, 3,000 rpm, 4°C). Supernatant
was decanted and cell pellets were packed for paraffin-
embedding (Tissue-Tek). FFPE samples were sectioned
at 5 μm onto positively charged microscope slides
( V W R ,W e s tC h e s t e r ,P A ,U S A )a n ds t o r e da t4 ° C .
Macrodissection of FFPE sections to be analyzed by the
HER1 VeraTag™ assay was performed to obtain sec-
tions with >70% tumor.
A l lb r e a s tt u m o rt i s s u e sw e r ea c q u i r e df r o mas i n g l e
commercial vendor (Asterand, Detroit, MI, USA), which
was chosen as our supplier because of their rigorous
controls around tissue collection, preparation and sto-
rage. Specifically, all tissues (median tumor length: 7
mm) were fixed or snap-frozen within 15 to 30 minutes
of excision. All tissues were fixed identically in neutral-
buffered formalin as dictated by the vendor’sS t a n d a r d
Operating Procedure, which is consistent with the
ASCO/CAP guidelines for preparation of breast tumor
tissue for HER2 testing.
Drug treatment
2C4 (Hybridoma from ATCC) was dissolved in sterile
PBS at a stock concentration of 1.73 mg/mL. Lapatinib
(American Custom Chemical Corporation, San Diego,
CA, USA) and erlotinib (extracted from tablets as
described in [40]) were each dissolved in dimethyl sulf-
oxide (DMSO) at a stock concentration of 5 mM and 10
mM, respectively. All compounds were stored at -80°C
until use. Cells were serum starved overnight and re-
serum starved the next morning as described above
prior to exposure to either 2C4 (2 μg/mL or 20 μg/mL),
lapatinib (0.1 μMo r1μM), erlotinib (0.1 μMo r1μM),
or carrier solution (1 × PBS or DMSO) for two hours at
37°C. Cells were then exposed or mock-exposed to 16
nM EGF for 10 minutes at 37°C. EGF stimulation was
terminated by washing with ice cold PBS and cells were
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described above.
Antibodies and peptides
All antibodies used in VeraTag™ assays and co-immu-
noprecipitation (co-IP)/Western blotting experiments
were monoclonal. HER2-Ab8 and HER2-Ab-15 (LabVi-
sion, Fremont, CA, USA) were directed against the
intracellular domain of HER2. HER2-Ab4 and HER2-
Ab5 (LabVision) were directed against the ECD of
HER2. HER2-Ab18 (Clone PN2A) was directed against
phosphotyrosine 1248 of HER2 (LabVision). Clone 6B12
was directed against phosphotyrosines 1221 and 1222 of
H E R 2( C e l lS i g n a l i n g ,D a n v e r s ,M A ,U S A ) .H E R 1 - A b 1 5
(LabVision) was directed against the intracellular
domain of HER1. HER1-Ab11 and HER1-Ab5 (LabVi-
sion) were directed against the HER1 ECD. Clones 53A5
(Cell Signaling) and 1H12 (Cell Signaling) were directed
against HER1 phosphotyrosines 1173 and 1068, respec-
tively. Clone 4G10 (Millipore, Billerica, MA, USA) was a
pan-phosphotyrosine antibody. For VeraTag™ assays,
antibodies were conjugated to either biotin or the Vera-
Tag™ fluorescent reporter pro11 (US Patent 7,105,308)
as described previously [38]. HER1-HER1 homodimeri-
zation was measured using an antibody to a single epi-
tope conjugated to either biotin or a VeraTag™
reporter [38].
Antigenic peptides for HER1-53A5 and HER1-1H12,
along with homologous HER2 peptides and non-phos-
phorylated HER1 and HER2 peptides, were synthesized
and HPLC-purified to >95% purity (Biomatik, Cam-
bridge, ON, Canada). Lyophilized peptides were resus-
pended in nuclease-free water to a concentration of 1
mg/ml.
VeraTag™ lysate and FFPE assay technology
VeraTag™ assays were performed as described pre-
viously [38,39] and as depicted in Figure 1. In brief, Ver-
aTag™ technology relies on the proximity of two
antibodies, one conjugated to biotin and the other
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Figure 1 Depiction of VeraTag™ technology. In both lysate and FFPE assays, one antibody conjugated to biotin and one antibody
conjugated to a VeraTag™ reporter bind to their respective analytes. Streptavidin-functionalized sensitizer dye binds to Ab-biotin. 670 nm light
causes singlet oxygen release, which induces cleavage and release of the VeraTag™ reporter molecule into illumination buffer (IB). IB is collected
and analyzed by capillary electrophoresis. For details, see Materials and methods.
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proN. For lysate assays, both conjugated antibodies were
incubated with cell or tumor lysates for one hour prior
to addition of streptavidin-coated beads that were
infused with the photosensitizer dye, methylene blue.
Four to eight serial dilutions of each lysate were run
over pre-blocked 96-well filter plates and washed three
times to retain the antibody-protein complexes bound
to the beads. The retained bead-antibody-protein com-
plexes were then suspended in illumination buffer (IB)
containing a fluorescein standard and two additional
capillary electrophoresis (CE) mobility markers in 0.01X
PBS [39]. Red light (670 nm wavelength) was shined on
the solutions using a customized LED illuminator to
activate the methylene blue photosensitizer molecule,
causing singlet oxygen to cleave the VeraTag™ reporter
at its thio-ester bond and release the fluorescent Vera-
Tag™ molecule. Samples were collected and analyzed
by CE (Applied Biosystems 3100) using customized
eTag Informer software. Measurement of VeraTag™
signals were in units of relative peak area (RPA), which
corresponds to the peak height integrated over the elu-
tion time of the released VeraTag™ reporter, normal-
ized to that of the internal fluorescein control. Results
for each of the serial dilutions were analyzed by linear
regression, and were reported as RPA/mg protein.
For FFPE assays, heat-induced epitope retrieval was
p e r f o r m e di ne i t h e rD i v aD e c l o a k e ro rB o r gD e c l o a k e r
(Biocare Medical, Concord, CA, USA) in a Decloaking
Chamber (BioCare Medical). Slides were washed with
water and blocked with blocking buffer (1.5% BSA in 1 ×
PBS, 1% mouse serum, plus protease and phosphatase
inhibitors), then incubated with the conjugated antibodies
in blocking buffer overnight. For peptide competition
assays, the antigenic peptides were co-incubated over-
night with the conjugated antibodies. The next morning,
slides were washed once with PBS + 0.25% Triton, then
once with PBS. Steptavidin bound to methylene blue
(SA-MB, US Patent 7,105,308) in 1 × PBS was added for
one hour, and slides were washed several times with PBS
+ 0.25% Triton and water in the dark prior to addition of
IB and exposure to red light for two hours at 4°C using a
customized LED illuminator. Slides were then further
incubated for one hour at room temperature. IB was col-
lected and VeraTag™ reporters were quantitated by
capillary electrophoresis (CE-Applied Biosystems 3100) in
duplicate, and RPA was determined with eTag Informer
software. For each sample, isotype control (ITC) assays
were also performed on an adjacent section, wherein the
specific biotin-conjugated antibody was substituted with a
biotin-conjugated ITC IgG. Following VeraTag™ FFPE
assay, all slides were subjected to hematoxylin and eosin
staining and submitted to analysis for tumor content by a
board-certified pathologist. Tumor area and section size
were quantitated using Image-Pro Plus 6.0 software
(Media Cybernetics, Bethesda, MD, USA). Cell line sec-
tions were considered to be 100% tumor, and, therefore,
the tumor area was equal to section size. Results were
reported as normalized RPA, which equals ((RPA*IB
volume)/tumor area) of the actual assayed section. In
some cases these results were reported with the ITC sub-
tracted. For HER2 total assays, results were reported as
HERmark
® score [39]. For the HER1-HER2 heterodimer
and activated assays, all samples were assayed with a
paired isotype control, and positives were classified as
those with greater than a low control cell line and with
assay signal greater than two-fold over isotype control
signal. The two-fold criterion was imposed because all
F F P Ea s s a ym e a s u r e m e n t sw e r er e p r o d u c i b l ew i t h i na
two-fold window (approximately 20% coefficient of varia-
tion); [39]), both within a single batch and between mul-
tiple independent batches (data not shown).
Optimal antibody concentrations were identified for
each lysate and FFPE assay as follows: Each antibody in
each assay was titrated both independently and depen-
dently to assure saturation of epitope in high-expressing
samples. Additionally, accuracy was assessed in both
ligand-dependent and ligand-independent models and
spanned the dynamic range of the HER analytes in the
tumor specimens. Detailed explanation of antibody opti-
mization for VeraTag™ assays can be found in [38] and
[39].
Co-immunoprecipitation (Co-IP)/Western blotting
Lysates (250 to 1,000 μg) were pre-cleared by incubation
with 40 to 80 μl protein G-sepharose beads (GE Health-
care, Buckinghamshire, UK) for one hour. Antibody was
added (either HER2-Ab8 or HER1-Ab15, 2-5 μg) to pre-
cleared lysates overnight at 4°C. Protein G-sepharose
beads (GE Healthcare) were added and incubated 1.5
hours on a rotator at 4°C. Beads were retained after cen-
trifugation (two minutes, 1,000 rpm, 4°C) and washed
twice with 1 × PBS and once with 50 mM Tris-HCL,
pH 8.0. Beads were resuspended in Laemmli Sample
Buffer (Bio-Rad, Hercules, CA, USA) and incubated at
90°C for 10 minutes. Proteins were separated by electro-
phoresis using 5% or 7.5% Tris-HCl Ready Gels (Bio-
Rad) and transferred to Immuno-Blot PVDF membranes
(Bio-Rad). Membranes were blocked for two hours with
5% milk in 1 × PBS + 0.25% Tween 20 (PBS-T) at room
temperature. Membranes were incubated overnight at 4°
C with the detection antibody in 5% milk + PBS-T.
Membranes were washed three times with PBS-T. Goat-
anti-mouse-HRP (Bio-Rad, Hercules, CA) or anti-rabbit-
HRP (Cell Signaling, Danvers, MA, USA) was then
added for two hours, and bands were detected using
Supersignal West Pico or Femto substrate (Thermo-
Scientific, Fremont, CA, USA).
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HER1 IHC was performed by a variation of the Zymed/
Invitrogen method, using pepsin (Digest-All, #00-3009;
Invitrogen, Carlsbad, CA, USA) and 31G7 monoclonal
antibody (#08-4205; Invitrogen). 31G7 concentration was
optimized on FFPE cell line controls and tumor sections
a n du s e da t0 . 4u g / m Lf o ro n eh o u r ,f o l l o w i n gp e p s i n
retrieval for 30 minutes at room temperature. All addi-
tional steps were performed per manufacturer’s protocol.
Flow cytometry
Cells were harvested by trypsinization and counted. Cells
were plated in a 96-well plate and labeled with HER2-
Ab4-biotin (Lab Vision) or HER1-Ab11 (Lab Vision) or
isotype control (mouse IgG1, BD Biosciences) at a con-
centration of 4 μg/ml in 100 μl total volume. The cells
were incubated with antibody on ice for 45 minutes and
washed twice with 1X PBS, followed by labeling with R-
Phycoerythrin-Avidin (Invitrogen, Carlsbad, CA) at 2 μg/
ml for 30 minutes on ice. The labeled cells were washed
twice with 1X PBS and fixed with 1% paraformaldehyde
in 1X PBS. Cells were analyzed on a FACSCalibur cyt-
ometer (BD Biosciences, San Jose, CA, USA). PE fluores-
cence intensity of labeled cells was determined on a FL2
(585/42 nm band pass filter) detector. Determination of
HER1 or HER2 receptor numbers were based on a cali-
brated standard curve using Quantum PE MESF Kit
(Bangs Laboratories, Inc., Fishers, IN, USA).
Results
Identification and characterization of HER1, HER2, and
HER1-HER2 heterodimer-expressing cell lines by
VeraTag™ lysate assay
In order to measure a HER1 and HER2 heterodimeric
complex and associated receptor phosphorylation levels,
assays of cell lysates were developed utilizing the Vera-
Tag™ technology (Methods; Figure 1). Preliminarily,
several cell lines were identified that contained varying
levels of these receptors as measured by flow cytometry
(Table 1). To optimize the HER1-HER2 VeraTag™
lysate dimer assay, a matrix of antibodies and conditions
were tested for maximal EGF-dependent signal induc-
tion in three cell lines that have high levels of HER1
and HER2 expression (SKOV3, SKBR3, and AU565) as
measured by flow cytometry. Minimal signal was
expected in negative control cell lines MDA-MB-453
and MDA-MB-468, expressing about 5,000 HER1 or
1,000 HER2 receptors per cell, respectively. Time course
experiments of ligand activation revealed that 10 to 30
minutes of exposure to either 10 or 100 nM EGF
yielded the highest levels of both HER1-HER1 homo-
and HER1-HER2 heterodimers (data not shown); there-
fore, the experiments described here utilized stimulation
conditions of 100 nM EGF for 10 minutes (37°C).
Consistent with the overexpresson of HER1 and HER2
as measured by flow cytometry (Table 1), AU565,
SKBR3, and SKOV3 cells all displayed high levels of
HER1-HER2 heterodimer upon stimulation with EGF
(Figure 2a). The cell line H1650, expressing HER1 levels
similar to that of SKOV3, but approximately 10-fold
lower HER2 expression, showed intermediate HER1-
HER2 heterodimer levels upon induction with EGF. No
HER1-HER2 signal was apparent in MDA-MB-453 or
MDA-MB-468, consistent with these cell lines having
very low levels of HER1 or HER2, respectively. All of
the cell lines with EGF-induced HER1-HER2 signal also
displayed ligand-independent HER1-HER2 signal to
varying degrees, consistent with recent reports that HER
family receptors may readily form ligand-bound, stable
dimers in an active complex, and ligand-independent,
less stable dimers as active or inactive complexes
[10-14,41,42].
Exposure to EGF can induce formation of both HER1-
HER2 heterodimers (Figure 2a) and HER1-HER1 homo-
dimers (Figure 2b) in the six cell lines tested, the relative
levels of which depended on the HER1 and HER2 total
receptor expression, which were also measured by lysate
assays and were unaffected by EGF stimulation (Figures
2c, d). In fact, both ligand-dependent and ligand-inde-
pendent HER1-HER2 heterodimer signal trended with
HER2 levels (Figure 2a), which was also observed in a
series of stably transfected HEK293 cells engineered to
overexpress similar amounts of HER1 with increasing
amounts of HER2 in the same cell background (Figure
S1 in Additional File 1). Taken together, these data
demonstrate the ability of VeraTag™ assays to quantita-
tively measure levels of HER1 hetero- and homodimers
in tumor cell line lysates, and indicate a dependency of
HER1-HER2 heterodimers on the levels of HER1 and
HER2.
Development of HER1-HER2 VeraTag™ FFPE assays
In order to evaluate HER1-HER2 activated forms as
potential biomarkers of targeted drug response, cell
Table 1 HER1 and HER2 receptor number in the cell line
panel
Cell line HER1 HER2
AU565 204,560 1,447,688
SKBR3 143,599 1,402,832
SKOV3 387,771 657,0880
H1650 158,872 53,810
MDA-MB-453 5,316 292,984
MDA-MB-468 3,389,807 1,209
HER1 and HER2 receptor numbers were determined by FACS analysis. Cells
were re-fed with fresh serum-containing media the night prior to harvesting
by trypsinization and FACS analysis. HER1 and HER2 receptor number
determination was based on a calibrated standard curve.
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Figure 2 Cell line panel in VeraTag™ lysate assays. Cartoons to the left of each graph depict the configuration of the antibodies in the
corresponding assay. Experiments were performed using a duplicate eight-point titration of protein input. Points in the linear range were used
to calculate RPA/mg protein. Gray bars represent signal from non-stimulated cells and black bars represent stimulation with 100 nM EGF for 10
minutes. A) HER1-HER2 heterodimer. B) HER1-HER1 homodimer. C) HER1 total. D) HER2 total.
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just described were utilized to develop VeraTag™ assays
that measure HER1-HER2 heterodimerization and acti-
vation in FFPE tumor tissue (Figure 3a). HER1 and
HER2 antibodies were identified and conditions opti-
mized for the highest signal to background detection of
HER1-HER2 heterodimers. The HER1 and HER2 anti-
bodies were previously shown to be specific by Western
blot and by individual HER1 [38] and HER2 (HER-
mark
®) FFPE assays [39]. HER1-HER2 heterodimer
assays of FFPE AU565, SKBR3, and SKOV3 cells all dis-
played specific signal two- to four-fold above an isotype
control background (Data not shown, Materials and
methods). Negative control cell lines MDA-MB-453 and
MDA-MB-468 lacked specific HER1-HER2 signal
(Figure 3). Consistent with the HER1-HER2 VeraTag™
lysate assay, 1.5- to -3-fold EGF-dependent increases
over ligand-independent signal was observed (Figures 2
and 3). This assay format was confirmed by co-IP/Wes-
tern blots, in which AU565, SKBR3, SKOV3, and H1650
showed an increase in HER1-HER2 dimerization while
MDA-MB-453 was negative. Control experiments indi-
cate that the strong bands detected for stimulated and
unstimulated MDA-MB-468 were a result of nonspecific
binding of the excessive amounts of expressed HER1 to
Protein G beads (data not shown).
In order to discern active HER1-HER2 complexes,
FFPE assays that detected phosphorylated forms of
HER1, HER2, and the HER1-HER2 heterodimeric com-
plex were developed. Based on target specificity, assay
vTag B
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Page 8 of 18dynamic range, and effects of EGF stimulation, the opti-
mal antibody pairing for measurement of activated
HER1-HER2 heterodimers utilized a HER2-specific anti-
body together with a HER1 antibody specific for the
kinase domain phosphotyrosine 1173 to produce a
pHER1-HER2 assay (Figure 3b). An EGF-dependent sti-
mulation range of two- to six-fold was observed for acti-
vated pHER1-HER2 heterodimers in the FFPE positive
controls cell lines, whereas the negative control cells did
not display EGF-dependent differences. Similar relative
levels of ligand-activated complexes or negative controls
were confirmed by co-IP/Western blots (Figure 3b).
Since HER1 and HER2 kinase domains share extensive
homology, including the HER1 pY1173 and correspond-
ing HER2 pY1248 regions, we confirmed that the mono-
clonal 53A5 antibody utilized in the pHER1-HER2 assay
was specific to phosphorylated HER1 using peptide
competition assays (Figure S2 in Additional File 1).
Taken together, these results support the antibody spe-
cificity of the pHER1-HER2 VeraTag™ assay in FFPE
cells.
HER1 and HER2 may be phosphorylated due to
actively signaling HER1-HER2 heterodimers, but other
mechanisms such as HER1-HER1 dimerization, HER2
autophosphorylation, or via dimerization with other
H E Rf a m i l ym e m b e r sm a ya l s op l a yar o l e .T h u s ,a s s a y s
were designed that could independently assess phos-
phorylated HER1 and phosphorylated HER2 in FFPE
tumor cells. Two phospho-HER1 (pHER1) assays were
developed, both of which utilized a HER1 antibody that
was matched with either an antibody to measure a spe-
cific HER1 phosphotyrosine site (pY1173; clone 53A5),
or a pan-phosphotyrosine antibody to measure general
HER1 and HER1-associated phosphorylation (pY: clone
4G10). Both the pHER1(1173) and the pHER1(pan)
assay formats led to similar trending of pHER1 signal
from the cell line panel, consistent with results from co-
IP/Western blots (Figure 3c, d). The similar assay pro-
files of the specific and pan-HER1 phosphorylation illus-
trate the specificity imparted by the dual antibody
system; 4G10 specifically detected HER1 phosphotyro-
sine due to proximity to the specific HER1 antibody.
To measure the levels of activated HER2, a phos-
phorylated HER2 assay was developed by pairing a
HER2 antibody with the pan-phosphotyrosine antibody
4G10 (Figure 3e). Intriguingly, the EGF-induced signal
from the pHER2 assays trended with that of the pHER1-
HER2 assay. Since the 53A5 antibody did not cross-react
with phospho-HER2, and since HER1 receptor levels in
AU565, SKBR3, SKOV3, and H1650 were within two-
fold of each other (Table 1), the differences in HER1-
HER2 activation were driven primarily by the amount of
HER2 in these cell lines.
Application of VeraTag™ technology to elucidate drug
mechanism of action
The direct measurement of ligand-independent and
-dependent HER dimers and phosphorylated forms by
the VeraTag™ assays allowed the mechanistic character-
ization of the acute effects (time = 2 hours) of the HER-
targeted drugs 2C4, lapatinib, and erlotinib. Cell stimu-
lations were performed with 16 nM EGF instead of 100
nM EGF, which may more closely approximate physio-
logic conditions while ensuring the same level of dimeri-
zation response. Exposure of 2 or 20 ug/mL 2C4, a
HER2 monoclonal antibody which inhibits HER2-HER3
heterodimerization [43], decreased EGF-dependent
HER1-HER2 heterodimer formation with a small conco-
mitant increase in HER1-HER1 homodimerization (Fig-
ure 4a). 2C4 had no significant effect on ligand-
independent HER1-HER2 heterodimerization. EGF-
dependent HER2 phosphorylation was diminished by
three-fold, while HER2 phosphorylation in the absence
of EGF was unaffected. A small decrease in EGF-depen-
dent HER1 phosphorylation was observed. In SKBR3,
with higher HER2 levels, 20 μg/ml of 2C4 was required
to observe loss of HER1-HER2 heterodimerization (data
not shown). These results are consistent with 2C4 being
an inhibitor of ligand-activated HER2 heterodimeriza-
tion and phosphorylation but not of ligand-independent
HER2 heterodimerization. Furthermore, VeraTag™
measurements also revealed a modest increase in ligand-
and 2C4-dependent HER1 homodimers that may result
from an increased pool of free HER1 that is no longer
able to associate with HER2. A HER2-HER3 VeraTag™
lysate assay [31] confirmed that the concentrations of
2C4 used here caused loss of heregulin-induced HER2-
HER3 heterodimerization in MCF7 cells, a well-charac-
terized activity of 2C4 (data not shown) [42,44,45].
As expected, lapatinib, a dual HER1 and HER2 tyro-
sine kinase inhibitor, nearly eliminated both HER1 and
HER2 phosphorylation in SKOV3 cells (Figure 4b).
Interestingly, acute treatment with lapatinib also caused
loss of EGF-dependent HER1-HER1 homodimerization,
b u td i dn o ta f f e c tH E R 1 - H E R 2h eterodimization in this
cell line. Since lapatinib has high affinity to HER2, the
effects of lapatinib were tested on H1650 cells that have
a similar number of HER1 receptors but approximately
10-fold less HER2 than SKOV3. In H1650 cells a
decrease in HER1-HER2 heterodimerizaton but not
HER1-HER1 homodimerization was detected (Figure
S3A in Additional file 1). The decreased inhibition of
HER1 homodimerization in H1650 cells is consistent
with an observed residual HER1 phosphorylation. The
insensitivity of HER1-HER2 heterodimers to lapatinib
disruption in SKOV3 cells and increased sensitivity in
H1650 cells, with reciprocal effects observed for HER1
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block relatively low, but not high, levels of HER1-HER2
or HER1 homodimers that are cell line- and HER level-
dependent (Figure 2). On the other hand, erlotinib, a
more selective HER1 tyrosine kinase inhibitor, stabilized
EGF-dependent HER1-HER2 heterodimers in SKOV3
cells while having little effect on HER1 homodimeriza-
tion (Figure 4c). These effects were similar in H1650
cells (Figure S3B in Additional file 1). In both cell lines,
erlotinib suppressed EGF-dependent HER1 and HER2
phosphorylation, with HER1 phosphorylation more
effectively inhibited relative to HER2, consistent with
the reported HER1 selectivity of erlotinib. These results
are consistent with several studies showing that HER1
tyrosine kinase inhibitors may stabilize inactive HER1-
containing dimers, most notably gefitinib binding to the
open or active HER1 kinase conformation [46-48]. Here,
EGF-dependent HER1-HER2 heterodimers were
stabilized by erlotinib but no effect on HER1-HER1
homodimers was observed (Figure 4c), which may repre-
sent a specific drug action of erlotinib.
The dynamic changes in the levels of EGF-dependent
HER1-HER2 heterodimers supported by 2C4 inhibition
and erlotinib stabilization were utilized to establish the
validity of these measurements in FFPE tumor cell lines.
SKOV3 cells were exposed to either 2C4 or erlotinib
and EGF as described above, fixed and made into FFPE
blocks, and measurements were made by VeraTag™
FFPE assays. Consistent with results from the lysate
assays, EGF-dependent HER1-HER2 heterodimerization
was suppressed whether measured using the HER1-
HER2 or the pHER1-HER2 assay. A decrease in HER2
phosphorylation was detected with the pHER2(pan)
assay, while minimal change was observed in HER1
phosphorylation as detected by either the pHER1(pan)
or pHER1(1173) assays (Figure 5). Upon erlotinib
AB
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Figure 4 Effects of HER1-HER2 axis inhibitors measured by VeraTag™ lysate assays. SKOV3 cells were serum-starved overnight then
treated with 2C4, erlotinib, or lapatinib for two hours at the indicated concentrations, in units of μg/mL for 2C4 and in μM for erlotinib and
lapatinib. A final concentration of 16 nM EGF was added or mock-added to the drug-containing media for 10 minutes prior to harvesting cells
for lysate or FFPE. VeraTag™ lysate assays were used to examine A) effects of 2C4, B) effects of lapatinib and C) effects of erlotinib on HER1-
HER2 heterodimerization (top row), phosphorylation of HER2 (second row), phosphorylation of HER1 (third row), and HER1-HER1
homodimerization (bottom row). Each experiment, beginning with a new growth of SKOV3 cells, was performed twice with consistent results.
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Page 10 of 18exposure, phosphorylation of HER1 was diminished as
evidenced by the decrease in signal in pHER1(pan),
pHER1(1173) and pHER1-HER2 assays. Inactive HER1-
HER2 heterodimers were stabilized as observed in the
lysate assays. A significant decrease in HER2 phosphory-
lation was not detected, in contrast with results from
the lysate assay in which a twofold decrease was
observed (Figure 4). This may be a reflection of a some-
what lower sensitivity of drug effects measured by the
FFPE-based VeraTag™ assay, relative to the VeraTag™
lysate assay. Taken together, these results indicate that
several dynamic changes in HER1-HER2 heterodimeriza-
tion and activation promoted by HER targeted drugs
and observed in cell lysates can also be detected in
FFPE tumor cells by specifically designed VeraTag™
assays.
Analysis of the HER1-HER2 axis in high HER2 breast
tumors
To determine the prevalence of HER1 and HER1-HER2
dimeric and activated forms in HER2-positive breast
cancer, 43 breast tumors that were pre-selected for high
HER2 expression by IHC and subsequent scoring using
the Allred system [49] (Asterand, Detroit, MI, USA)
were analyzed by HER1-HER2 VeraTag™ FFPE tissue
assays. Of these tumors, 39 were HER2 positive by the
HERmark
® breast cancer assay [39], consistent with
their independently determined Allred = 6 to 8 category
scores. Total HER1 was measured in these tumors by
VeraTag™ FFPE cell assay as described [38], with modi-
fications (see Materials and methods). A total of 16 of
the 39 FFPE tumors that were HER2 positive also dis-
played VeraTag™ HER1 signal that was greater than
that of cell line MDA-MB-435, which expresses approxi-
mately 10,000 HER1 receptors/cell by flow cytometry
(data not shown). A second format of the HER1 Vera-
Tag™ assay, which utilized an antibody directed against
the ECD rather than the ICD of HER1, was run on a
subset of 30/43 tumors upon which macrodissection of
non-tumor elements were performed (see Materials and
methods). The ICD and ECD assays correlated signifi-
cantly for both intact (R = 0.4885, P = 0.0113; Figure
S4A in Additional file 1) and macrodissected samples (R
= 0.5269, P = 0.0068; Figure S4B in Additional file 1). A
comparison of intact tumor sections, containing repre-
sentation of stroma, fat, tumor and normal epithelia,
with the macrodissected sections in the ECD assay
yielded nearly identical results (R = 0.8964, P < 0.0001;
Figure S4C in Additional file 1). Taken together, these
results suggest that the HER1 signal generated by the
VeraTag™ assay was predominately derived from
epithelial tumor cells in this sample set, although others
have observed HER1 in normal epithelium [50]. There is
general agreement between the tumor cell HER1 mea-
sured by IHC or HER1 VeraTag™ assays of macrodis-
sected breast tumors (Figure S5A in Additional file 1).
Analysis of HER1 IHC by a board certified pathologist
further supported that the majority of the HER1 signal
Ligand-dependent effects of 2C4 (2 ug/mL) and erlotinib (1uM) on SKOV3 in
FFPE VeraTag assays
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Figure 5 EGF-dependent effects of 2C4 and erlotinib measured by VeraTag™ FFPE assays. SKOV3 cells were treated as described for
Figure 4, but cells were fixed and made into FFPE blocks instead of lysed. Each VeraTag™ FFPE assay, listed on the X-axis, was performed on six
slides. Results are depicted as the ratio of the normalized RPA of EGF and drug-exposed cells to the normalized RPA of cells that were exposed
to EGF alone. Gray bar: 2C4. Black bar: Erlotinib. Values above the dashed line at ratio = 1 represent stabilization due to drug exposure, and
values below the dashed line represent inhibition due to drug exposure.
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Page 11 of 18was derived from tumor cells rather than normal tissue
(Figure S5C-J in Additional file 1).
Most HER1 and high HER2 expressing tumors
expressed HER1 at low to moderate levels (IHC category
1 + ,2 + ) ,w h e r e a s2o f4 3s a m p l e st h a th a dh i g hH E R 1
levels by VeraTag™ a s s a ya n dH E R 1I H Cw e r en o t
HER2-positive by HERmark
® (Figure S5B in Additional
File 1). Although this suggests that HER1 is not highly
co-expressed with HER2 when HER2 is overexpressed,
it is consistent with the possibility of ligand-dependent
and independent HER1-HER2 heterodimerization in
HER2-positive breast cancer cells.
To evaluate the breast tumors with the HER1-HER2
heterodimer and activated assays, all samples were ana-
lyzed with a paired isotype control, and positives were
classified as described in the Methods. Heterodimer sig-
nals in the tumors classified as positive were greater
than or equal to that of cell line H1650 stimulated with
100 nM EGF. HER1-HER2 heterodimers were detected
in 4 of the 16 tumors that were classified as positive for
both HER1 and HER2, and pHER1-HER2 heterodimers
were detected in 8 of these 16 tumors. The two hetero-
dimer measurements were likely discrepant since the
p H E R 1 - H E R 2a s s a ya p p e a r st ob em o r es e n s i t i v ea n d
may be able to detect lower levels of analyte.
Different molecular species within the HER1/HER2
axis were compared to one another for possible relation-
ships. Phospho-HER2 trended linearly with HER2 total
measurements (Spearman R = 0.4728, P =0 . 0 0 1 )( F i g u r e
6c). However, pHER2 measurements spanned a range of
up to one log or greater for any given HER2 total level,
supporting potential utility of pHER2 to further stratify
HER2 positive tumors, if similar levels of phospho-pre-
servation were achieved. Phospho-HER1-HER2 measure-
ments correlated with HER1 (R = 0.5706, P < 0.0001) and
HER2 (R = 0.5228; P = 0.005) (Figure 6a, b). HER1-HER2
and pHER1-HER2 measurements correlated significantly
(R = 0.5091; P = 0.0007) (Figure 6d). The correlation
between total HER1 and total HER2 was not significant
(R = 0.1603, P = 0.2927) (Figure 6F). Similar results were
obtained from data corrected for isotype control back-
ground (data not shown). Additionally, a subset of
tumors having matched fresh frozen blocks were lysed
and analyzed by Western blot for HER1 and HER2, or by
co-IP/Western blots for pHER2 and pHER1-HER2 het-
erodimers (Figure S6 in Additional file 1). Results con-
firm the presence or absence of the different HER forms
detected by VeraTag™ assays, with relative amounts gen-
erally consistent but some variation likely due to the
semi-quantitative nature of Western blots, variable
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Figure 6 Comparison of HER1/HER2 assay analytes in breast tumors pre-selected for HER2 positivity. A) Phospho-HER2 correlations with
total HER2. B) Phospho-HER1-HER2 correlates with total HER2. C) Phospho-HER1-HER2 correlates with total HER1. D) Phospho-HER1-HER2
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tation, phosphoprotein and dimer stability versus FFPE
preservation, and tumor heterogeneity within matched
FFPE and fresh-frozen/lysed patient samples.
Discussion
Using VeraTag™ technology, we have developed multi-
ple quantitative and sensitive assays for measurements
of activated receptor species in the HER1-HER2 signal-
ing axis in both breast tumor cell lysates and FFPE cell
and tumor formats. Using the VeraTag™ assay for cell
lysates, control cell lines were identified which expressed
different levels of HER1 and HER2, and generated a
range of ligand-dependent and independent levels of
phosphorylated HER proteins and HER1-HER2 hetero-
dimers. These findings were confirmed by co-immuno-
precipitation analysis. The cell lines were then utilized
in the development and characterization of VeraTag™
assays that measured activated HER1/HER2 forms in
FFPE tumor cells. Both the VeraTag™ lysate and FFPE
cell assays demonstrated utility in the study of drug
action and in the evaluation of activated HER1/HER2
forms in HER2-positive breast tumor tissue. Taken
together, these studies indicate that VeraTag™ assays
can be utilized in preclinical studies of drug mechanism
of action involving both protein phosphorylation and
protein-protein modes of signal activation, and has the
potential for use in the in situ measurement of activated
signal proteins in FFPE tumors toward biomarker identi-
fication in patient samples.
Several specific findings were made through the appli-
cation of the VeraTag™ lysate assays. First, the levels of
ligand-dependent and independent HER1-HER2 hetero-
dimers appear to depend on the levels of HER1 and
HER2. These results are consistent with recent studies
indicating the existence of ligand independent HER1-
HER2 and HER2-HER3 heterodimers [10-14,42,51] and
suggest the possibility of elevated basal signaling in the
presence of overexpressed HER receptors. Increased
levels of ligand-independent HER1-HER2 heterodimers
were also observed in high HER1 and HER2 expressing
cell lines prepared by the cell lysate or FFPE cell for-
mats. Although the levels of HER1-HER2 and pHER1-
HER2 heterodimers display a dependency on HER1 and
HER2 expression, a range of heterodimer signal is
observed for a given level of HER1 or HER2. To the
extent that levels of HER1-HER2 heterodimers may pro-
vide unique biological information beyond that of HER1
and HER2 expression together or alone will likely
require clinical evaluation. Second, we made several
novel observations regarding drug effects on the HER1/
HER2 receptor axis. Pertuzumab, the humanized version
of the monoclonal antibody 2C4 that binds to the
dimerization arm of HER2 [43,52], has also been
described as an inhibitor of HER2-HER3 heterodimeri-
zation, downstream signaling, and tumor cell growth
[53]. More recent work has supported an additional role
for 2C4 in inhibition of HER1-HER2 heterodimerization
[44,45] although one group has shown 2C4 stabilization
of this complex [54]. Results of the HER1-HER2 Vera-
Tag™ lysate assay on SKOV3 and two other cell lines
(H1650 and SKBR3), acutely exposed to 2C4 prior to
EGF stimulation, were consistent with 2C4 acting as an
inhibitor of HER1-HER2 heterodimerization. Intrigu-
ingly, an increase in HER1-HER1 homodimerization was
observed in all three cell lines investigated, consistent
with a shift in HER2 receptor availability for binding to
HER1. EGF-dependent HER2 phosphorylation was
decreased significantly while ligand-independent phos-
phorylation was unaffected, suggesting that transpho-
sphorylation of HER2 by HER1 was inhibited by 2C4,
while HER2 autophosphorylation or phosphorylation by
other sources was not. These results are consistent with
a pattern of ligand-activated HER2 heterodimerization
inhibition by 2C4 [42-44,53].
Additional novel observations were made from Vera-
Tag™ lysate analysis of drug effects of the 4-quinazoline
tyrosine kinase inhibitors lapatinib and erlotinib. Lapati-
nib is a small molecule tyrosine kinase inhibitor (TKI)
of both HER1 and HER2 [55], and erlotinib is a TKI
that preferentially inhibits HER1 [56,57]. As expected,
lapatinib exposure suppressed both HER1 and HER2
phosphorylation, supporting validity of VeraTag™ lysate
assays to detect these measurements. Not only did erlo-
tinib exposure suppress HER1 phosphorylation, but it
also decreased EGF-dependent HER2 phosphorylation in
a pattern similar to that of 2C4. This is consistent with
loss of HER1-dependent HER2 transphosphorylation. In
contrast to 2C4, however, erlotinib stabilized EGF-
dependent HER1-HER2 heterodimers in all three cell
lines investigated. These heterodimers were inactive
since phosphorylation of both receptors was inhibited,
with a preference for HER1 inhibition in high HER2
SKOV3 cells. These results support previous co-immu-
nopreciptation and cross-linking studies suggesting that
members of this quinazoline family of TKIs may stabi-
lize inactive HER heterodimers while inhibiting phos-
phorylation and downstream signaling [46-48].
Mechanistic and structural studies indicate that erlotinib
binds to the open, active conformation of HER1 kinase
domain [58], while lapatinib binds to the closed, inactive
conformation [55]. Here, erlotinib may have enabled
trapping of HER1 in the open, active conformation that
promotes HER dimerization as observed for gefitinib
[48], leading to an increase in detectable but inactive
HER1-HER2 heterodimers. Lapatinib, however, did not
stabilize HER1-HER2 heterodimers. Intriguingly, lapati-
nib suppressed HER1-HER1 homodimerization in the
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H1650 cells that have lower HER2 levels relative to
SKOV3 cells and thus less HER1-HER2, HER1-HER2
heterodimers decreased but HER1-HER1 homodimer
levels were unaffected. Since lapatinib inhibits both
HER1 and HER2, we hypothesize that the discrepancy
in dimerization inhibition pattern between SKOV3 and
H1650 may be due to the proportion of HER1 and
HER2 receptors. In cell lines that predominantly signal
through HER1-HER2, the reduced levels of HER1-HER1
dimer and pHER1 may be more sensitive to inhibition
by a dual kinase inhibitor at the concentrations tested
here, while the opposite would be true in cell lines that
signal predominantly through HER1-HER1 dimerization.
Further experiments are needed to confirm this
hypothesis.
VeraTag™ assays on FFPE cell line sections utilizing
2C4 and erlotinib were consistent with results from
lysate assays and with expectations from published
results, supporting utility and extending the use of these
assays in understanding receptor activation in cell lysate
and FFPE tumor tissues. To the best of our knowledge,
this is the first example of HER1-HER2 heterodimer
measurements made in FFPE tissue that have been char-
acterized using drug inhibition, and suggests application
to both cell-based and in vivo drug studies. Further, our
studies have suggested interesting biology regarding
HER1 and HER2 receptor switching. While findings are
preliminary, they are suggestive of the ability of cell
lines to redistribute signaling patterns between HER1-
HER1 homodimers and HER1-HER2 heterodimers
depending on relative HER levels, acute drug exposure
and mechanism of drug action.
Last, we utilized the HER1/HER2 FFPE cell assays to
determine the prevalence of HER1-HER2 dimers and
phosphorylated forms in 43 breast tumor samples that
were pre-selected for HER2-positivity. Of the 16 tumors
that co-expressed HER1, 25% had detectable HER1-
HER2 heterodimers whereas 50% had detectable
pHER1-HER2. Phosphorylation of HER2 was detected in
more than 50% of the HER2-positive tumors. Both
autophosphorylation and transphosphorylation due to
heterodimerization may contribute to overall HER2
phosphorylation, and both may be relevant in determin-
ing patient treatment. Historically, there has been a
reluctance to measure phosphorylation in FFPE tissues
due to the potential for phosphatase activity during
tumor excision and time to fixation. However, recent
technical advances to stabilize phosphorylation, such as
decreased time to fixation and addition of phosphatase
inhibitors to the fixative solution, along with increased
evidence for the utility of phosphoprotein measure-
ments, support development of technologies to specifi-
cally and quantitatively measure phosphoproteins in
FFPE tissues. Phosphorylated HER2 has been shown to
be a predictor of poor response and survival in breast
cancer patients in multiple studies [59-61]. In a study of
816 archival FFPE breast cancer tissues, HER2-positive
patients could be further stratified by pHER2 status, and
those with pHER2 detected by IHC had lower survival
rates than those that did not [62]. Tumors co-expressing
pHER2 and pHER3 correlated with response to lapatinib
in a Phase II clinical study of advanced inflammatory
breast cancer patients [63]. Recently, a study utilizing
Reverse Phase Protein Microarray identified a subset of
breast tumors from the I-SPY clinical trial that were
HER2 negative (unamplified) by Fluorescence In Situ
Hybridization (FISH) and IHC, but showed dispropor-
tionately high pHER2 and downstream signaling [64].
Ongoing studies will determine clinical significance of
this subset. Measurements of phosphorylated HER1,
while not as prevalent in the majority of HER2-positive
breast tumors, may also aid in prediction of response to
targeted therapies in de novo or acquired Herceptin-
resistant breast cancers as well as multiple additional
cancer types, including squamous cell carcinoma of the
head and neck, lung, gastric, and triple-negative breast
cancers [65-71]. Studies utilizing pHER1 VeraTag™
FFPE assays in such cancers are currently underway in a
subset of these cancer types.
In our study, great care was taken to preserve phos-
pho-protein epitopes. All tumor tissues were acquired
from a single commercial vendor that utilized a rigorous
protocol for tumor collection, fixation, and storage to
promote preservation of epitopes, consistent with the
ASCO/CAP guidelines for preparation of breast tumor
tissue for HER2 testing (see Methods). Additionally, an
independent study performed under similar conditions
in tumor cell xenografts showed complete preservation
of pHER [72]. While it cannot be completely excluded,
such rigor in collection and fixation protocols minimizes
the potential for discrepancies in phospho-degradation.
A recent study showed that although the total time for
fixation influenced the retention of phosphoprotein epi-
topes detected by immunoassays, the phosphorylated
signaling proteins pAkt and pERK were relatively stable
for 30 to 80 minutes post excision when formalin fixa-
tion was facilitated by thin diameter core cuts (approxi-
mately 2 mm) compared to thicker resected tumor
tissues (median length = 29 mm) [73]. Despite the
decreased overall signal in the resected tissues, pAKT
and pERK levels significantly correlated with levels mea-
sured in core cuts [73], suggesting that these phospho-
measurements may have utility even under imperfect
conditions. Thus, although complete retention of pHER
may not have been achieved in the clinical studies just
described above, or in the present study, sufficient pre-
servation of pHER epitopes very likely occurred, since
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outcome in the prior studies, and with other relevant
VeraTag™ measurements in our study. Finally, while
interpretation of the phosphoprotein data in this tumor
set may be limited in terms of absolute value, our data
clearly illustrate the ability of VeraTag™ technology to
measure phospho-HER analytes in FFPE tissues, and can
be tested for possible clinical utility if stringent control
of cold ischemic time and phospho-epitope preservation
is employed with patient samples.
In sum, the VeraTag™ lysate assays presented here
may prove extremely useful when used in concordance
with preclinical drug development, while FFPE assays
may help fulfill the need for sensitive, quantitative meth-
ods for detection of activated HER1 and HER2 com-
plexes in FFPE tumor tissues. With the advent of
additional molecularly targeted therapies into the clinic,
a thorough understanding of receptor activation and
detection in patient samples has potential to enable the
measurement of biomarkers that may be more predic-
tive of drug response.
Conclusions
We have developed novel, quantitative assays that mea-
sure HER1-HER2 dimerization and phosphorylation,
HER1 phosphorylation, and HER2 phosphorylation in
both lysate and FFPE tissue formats using VeraTag™
technology. The VeraTag™ assays were used to charac-
terize the effects of 2C4, lapatinib, and erlotinib on cell
lines, and receptor signaling switching between HER1-
HER1 homodimers and HER1-HER2 heterodimers was
observed under some conditions. Further, HER1-HER2
heterodimers were detected in a subset of HER2-positive
breast tumors that co-expressed HER1. These Vera-
Tag™ assays may have utility both in pre-clinical drug
development and for predicting clinical response to tar-
geted agents.
Additional material
Additional file 1: Supplementary Figures S1 to S6 Figure S1.
Ligand-dependent and ligand-independent HER1-HER2
heterodimerization depends on receptor levels. A total of 293 cells
were transfected with HER1 to generate 293H1_clone11. Clone11 was
then co-transfected with HER2 to generate clones 12, 15, 16, and 19.
Gray bars represent signal from mock-stimulated cells, and black bars
represent signal from cells stimulated with 100 nM EGF. A) HER1 total
lysate assay. All clones had the same amount of HER1. B) HER2 total
lysate assay. Clones displayed different amounts of total HER2. C) HER1-
HER2 heterodimer lysate assay. Ligand-dependent and ligand-
independent HER1-HER2 heterodimer formation increased with
increasing HER2 receptor number in clones with the same amount of
HER1. Figure S2. Specificity of clone 53A5 for phospho-HER1 in FFPE
assay. AU565 FFPE slides from cells were mock-stimulated or stimulated
with 100 nM EGF for 10 minutes. The pHER1-HER2 FFPE assay was
performed, but peptide was incubated with antibody in molar ratios 1:0,
1:1, 1:10, or 1:100 of antibody to peptide. Gray bars represent signal from
mock-stimulated cells, and black bars represent signal from EGF-
stimulated cells. Phospho-HER1-HER2 signal is competed to basal levels
using the antigenic peptide H1pY1173 but not with the
nonphosphorylated H1Y1173 nor the homologous HER2 peptides
H2pY1248 nor H2Y1248. Figure S3. Effects of lapatinib and erlotinib
measured by VeraTag™™ lysate assays in H1650. H1650 cells were
serum-starved overnight then treated with lapatinib or erlotinib for two
hours at the indicated concentrations, in units of μM. A final
concentration of 16 nM EGF was added or mock-added to the drug-
containing media for 10 minutes prior to harvesting cells for lysate or
FFPE. VeraTag™™ lysate assays were used to examine A) effects of
erlotinib and B) effects of lapatinib on HER1-HER2 heterodimerization
(top row), phosphorylation of HER2 (second row), phosphorylation of
HER1 (third row), and HER1-HER1 homodimerization (bottom row).
Figure S4. Comparison of two different formats of a HER1 total
protein VeraTag™™ assay performed in HER2+ breast FFPE tumors.
A) Comparison of a HER1 ICD-directed total protein assay with a HER1
ECD-directed total protein assay, both applied to intact FFPE tumor
sections. B) Comparison of a HER1 ICD-directed total protein assay
performed in intact FFPE tumor sections with a HER1 ECD-directed total
protein assay having non-tumor elements macrodissected from the FFPE
tumor sections. C) Comparison of HER1 values measured in intact versus
macrodissected FFPE tumor sections assayed by the HER1 ECD-directed
total protein assay. Figure S5. Comparison of HER1 ECD-directed total
protein assay with HER1 IHC H-score. A) A subset of 30 HER2+ breast
tumors was assayed by a HER1 ECD-directed total protein assay with
non-tumor elements macrodissected away, and the HER1 levels were
compared with the tumor cell HER1 IHC H-scores measured on adjacent
sections. The IHC H-score spans 0 to 300. Tumors with an H-score of 0
were assigned a score of 0.1 to make plotting on a log scale possible. B)
The percentage of the 30 tumors at each HER1 IHC test category. C-F)
Micrographs of the HER1 IHC staining representing four separate invasive
ductal carcinoma breast tumors that are representative of other tumors
having similar staining intensity from IHC = 3+ to 0, respectively (4×
magnification). G-J) Same tumor micrographs as in C-F but at 20×
magnification. Figure S6. Western blot and co-IP/Western blots of
lysed tumor tissue homogenates. Fresh frozen tumors matched with
FFPE blocks of HER2+ breast tumors were lysed and homogenized with
protease and phosphatase inhibitors, and analyzed by SDS-PAGE and
Western blots. Sections of the matched FFPE blocks were assayed by the
comparable VeraTag™™ assay. A) HER2 Western blot comparison of
tumor lysate with HER2 total protein VeraTag™™ assay. B) HER1 Western
blot of tumor lysate comparison with HER1 ECD-directed total protein
VeraTag™™ assay. C) Tumor lysate immunoprecipitated with a HER2
antibody and Western blot with a pan-phosphotyrosine antibody
comparison with pHER2 VeraTag™™ assay. D) Tumor lysate
immunoprecipitated with pHER1(1173) antibody and Western blot with a
HER2 antibody comparison with pHER1-HER2 VeraTag™™ assay.
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